<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Parasit Vectors</journal-id><journal-id journal-id-type="iso-abbrev">Parasit Vectors</journal-id><journal-title-group><journal-title>Parasites &#x00026; Vectors</journal-title></journal-title-group><issn pub-type="epub">1756-3305</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27378450</article-id><article-id pub-id-type="pmc">4932752</article-id><article-id pub-id-type="publisher-id">1662</article-id><article-id pub-id-type="doi">10.1186/s13071-016-1662-7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Evaluation of protective efficacy induced by virus-like particles containing a <italic>Trichinella spiralis</italic> excretory-secretory (ES) protein in mice</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Su-Hwa</given-names></name><address><email>dltnghk228@nate.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Sang-Soo</given-names></name><address><email>goodmorning.kim@gmail.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Dong-Hun</given-names></name><address><email>hihool@naver.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Ah-Ra</given-names></name><address><email>kara9251@hanmail.net</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Quan</surname><given-names>Fu-Shi</given-names></name><address><email>fsquan@khu.ac.kr</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Department of Biomedical Science, Graduate School, Kyung Hee University, Seoul, South Korea </aff><aff id="Aff2"><label/>Department of Medical Zoology, Kyung Hee University School of Medicine, Seoul, South Korea </aff></contrib-group><pub-date pub-type="epub"><day>4</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>4</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>9</volume><elocation-id>384</elocation-id><history><date date-type="received"><day>3</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>6</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The frequent outbreaks of human trichinellosis globally underscore the need to develop effective vaccine. We hypothesized that a novel vaccine could improve vaccine efficacy against <italic>Trichinella spiralis</italic>.</p></sec><sec><title>Methods</title><p>In this study, we developed virus-like particles (VLPs) containing the 53 KDa excretory/secretory (ES) protein of <italic>T. spiralis</italic> and the influenza matrix protein 1 (M1) as a core protein, and investigated the protective efficacy of the VLPs alone or with cholera toxin (CT) in a mouse model.</p></sec><sec><title>Results</title><p>Intramuscular immunization induced <italic>T. spiralis</italic>-specific IgG, IgG1 and IgG2a antibody responses before and after challenge infections in the sera. These antibody responses were significantly enhanced in mice immunized with adjuvanted VLPs. Upon challenge infection, vaccinated mice showed significantly reduced worm burden in the diaphragm. Protective immune responses and efficacy of protection were significantly improved by immunization with VLPs together with CT adjuvant.</p></sec><sec><title>Conclusions</title><p>Our results are informative for a better understanding of the protective immunity induced by <italic>T. spiralis</italic> VLPs, and will provide insight into designing safe and effective vaccines.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13071-016-1662-7) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd><italic>Trichinella spiralis</italic></kwd><kwd>Virus-like particle</kwd><kwd>Cholera toxin</kwd><kwd>Vaccine</kwd><kwd>Protection</kwd></kwd-group><funding-group><award-group><funding-source><institution>the National Research Foundation of Korea (NRF) </institution></funding-source><award-id>NRF-2014R1A2A2A01004899</award-id><principal-award-recipient><name><surname>Quan</surname><given-names>Fu-Shi</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>the Agri-Bio Industry Technology Development Program, IPET, MAFRA, KHIDI</institution></funding-source><award-id>315030-03-1-HD020</award-id><principal-award-recipient><name><surname>Quan</surname><given-names>Fu-Shi</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Ministry of Health and Welfare (KR) </institution></funding-source><award-id>HI15C2928</award-id><principal-award-recipient><name><surname>Quan</surname><given-names>Fu-Shi</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Trichinellosis is a parasitic infection caused by <italic>Trichinella spiralis</italic>, which is a serious parasitic zoonosis and a globally endemic disease [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref>]. Human infection is commonly the result of eating raw or undercooked meat containing <italic>Trichinella</italic> larvae. Pork and its products are closely associated with outbreaks of human trichinellosis. The global prevalence of trichinellosis is difficult to evaluate, but as many as 11 million people may be infected. The frequent outbreaks of human trichinellosis globally underscore the need to develop an effective vaccine [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>]. The development of vaccines would have significant impact towards the ultimate goal of disease elimination [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p>Natural parasite extracts, recombinant protein, synthetic peptides, attenuated phage display and genetic immunization have been used for vaccine studies. Radiation, ultraviolet-attenuated or DNA-plasmid vaccines for <italic>Trichinella spiralis</italic> were found to be highly protective in experimental animals. However, such vaccines are not well suited for field use [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>].</p><p>Recombinant vaccines based on virus-like particles (VLPs) or nanoparticles have displayed promising safety and efficacy in preclinical and clinical studies [<xref ref-type="bibr" rid="CR12">12</xref>]. Virus-like particles resemble viruses, but do not contain any viral genetic material. Thus, they do not replicate, having advantages for safety [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR15">15</xref>]. VLPs contain repetitive high density displays of viral surface proteins, which present conformational epitopes that can elicit strong cellular and humoral immune responses [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Immunization with <italic>T. spiralis</italic> ES protein elicits a robust immune response, and resulted in complete protection against infective larvae [<xref ref-type="bibr" rid="CR16">16</xref>]. The 53&#x000a0;kDa protein of <italic>T. spiralis</italic> has been used as an immunomodulatory protein for treating inflammatory disease such as bowel diseases [<xref ref-type="bibr" rid="CR17">17</xref>]. The <italic>T. spiralis</italic> 53&#x000a0;kDa protein is reported to be a novel serological marker and vaccine candidate [<xref ref-type="bibr" rid="CR18">18</xref>]. The 53-kDa recombinant proteins provide early and species-specific antibody responses in mice infected with <italic>T. spiralis</italic> [<xref ref-type="bibr" rid="CR19">19</xref>]. However, there is no report on vaccine efficacy of <italic>T. spiralis</italic> 53&#x000a0;kDa against challenge infection. Thus, we were interested to test the hypothesis that <italic>T. spiralis</italic> 53&#x000a0;kDa protein in virus-like nanoparticle form could be an important immunogen which could induce humoral and/or cellular immunity.</p><p>To the best of our knowledge, in this study for the first time VLPs derived from parasite <italic>T. spiralis</italic> were produced. These novel VLPs containing <italic>T. spiralis</italic> 53&#x000a0;kDa protein and influenza matrix M1 as a core protein were evaluated as a potential vaccine. We also investigated the effect of CT as an adjuvant for the VLP vaccine.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Parasite, virus, cells and antibodies</title><p>Korean isolate of <italic>T. spiralis</italic> was obtained from specific pathogen-free female, inbred Sprague&#x02013;Dawley (SD) rats, aged 8&#x000a0;weeks, maintained by serial oral passage. Influenza virus (A/PR/8/34) was used to infect MDCK cells. <italic>Spodoptera frugiperda</italic> Sf9 cells were maintained in suspension in serum-free SF900II medium (Invitrogen, Carlsbad, USA) at 27&#x000a0;&#x000b0;C in spinner flasks at a speed of 130 to 140&#x000a0;rpm. Horseradish peroxidase (HRP)-conjugated goat anti-mouse immunoglobulin A (IgA) and G (IgG), IgG1 and IgG2a were purchased from Southern Biotech (Birmingham, USA).</p></sec><sec id="Sec4"><title>Preparation of <italic>T. spiralis</italic> antigen</title><p><italic>Trichinella spiralis</italic> excretory/secretory (ES) product was produced as described previously [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Larvae of <italic>T. spiralis</italic> were isolated from rat muscle tissue by artificial digestion and washed. Clean larvae were incubated in a CO<sub>2</sub> incubator for 24&#x000a0;h at 37&#x000a0;&#x000b0;C in Petri dish containing RPMI-1640 culture medium without FBS. The culture supernatants were collected by centrifugation. The supernatant was dialyzed and lyophilized. The protein concentration was determined by QuantiPro BCA Assay Kit (Sigma-Aldrich, St Louis, USA). <italic>Trichinella spiralis</italic> ES products were identified by SDS-PAGE (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Figure S1) and stored at -70&#x000a0;&#x000b0;C until use.</p></sec><sec id="Sec5"><title>Construction of rBV expressing <italic>T. spiralis</italic> (T653K) and influenza M1</title><p>Total RNA was extracted from the <italic>T. spiralis</italic> larvae using RNeasy Mini Kit (Qiagen, Valencia, USA). The RNA was reverse transcribed to cDNA using the Prime Script 1st strand cDNA synthesis kit according to the manufacturer&#x02019;s instructions (Takara, Otsu, Japan). The cDNA was used as a template to amplify the complete coding sequence of T653K by polymerase chain reaction (PCR). The primers were designed according to the nucleotide sequence of T653K in GenBank (accession number: DQ399914): forward (5&#x02032;-AAA GAA TTC ACC ATG TTC AGC ATC ACA TTA AA-3&#x02032;) and reverse (5&#x02032;-TTA CTC GAG TTA GAA CAA CAA CTG TAG T-3&#x02032;) with EcoRI and XhoI restriction enzyme sites. The PCR product was inserted into the pFastBac vector (Invitrogen, Carlsbad, USA). For M1 gene cloning, A/PR/8/34 virus was inoculated into MDCK cells and total viral RNA was extracted using an RNeasy Mini kit (Qiagen, Valencia, USA). Reverse transcription (RT) and PCR were performed on extracted viral RNA using the One-Step RT-PCR system (Invitrogen, Carlsbad, USA) with gene specific oligonucleotide primers. The following primer pairs were used forward, M1 (5&#x02032;- TCC CCC GGG CCA CCA TGA GCC TTC TGA CCG AGG TC -3&#x02032;); reverse, M1 (5&#x02032;- TTA CTT CTA GAT TAC TTG AAC CGT TGC ATC TG -3&#x02032;) with SmaI and XbaI restriction enzyme sites. Following RT-PCR, a cDNA fragment containing the M1 gene was cloned into the pFastBac vector (Invitrogen, Carlsbad, USA). The recombinant plasmid was transformed into <italic>E. coli</italic> DH5-alpha and transferred into a DH10-Bac. The nucleotide sequences of M1 (accession number: EF467824) and T653K (accession number; DQ399914.1) genes in the pFastBac vector were confirmed by DNA sequencing.</p></sec><sec id="Sec6"><title>Production of recombinant baculovirus and VLPs</title><p>Transfections of DNA containing the above genes were accomplished using cellfectin II (Invitrogen, Carlsbad, USA) with Sf9 cells as recommended by the manufacturer, followed by transformation of pFastBac containing T653K or influenza M1 with white/blue screening. The rBVs were derived by using a Bac-to-Bac expression system (Invitrogen, Carlsbad, USA). To produce VLPs containing T653K and M1, Sf9 cells were co-infected with rBVs expressing T653Kand M1. Cell culture supernatants were collected on day 2 or 3 post-infection, cleared by centrifugation at 6,000&#x000a0;rpm for 30&#x000a0;min at 4&#x000a0;&#x000b0;C to remove cells. VLPs in the supernatants were pelleted by high-speed centrifugation (45,000&#x000d7; <italic>g</italic> for 30&#x000a0;min). The sedimented particles were resuspended in phosphate-buffered saline (PBS) at 4&#x000a0;&#x000b0;C overnight and further purified through a 20&#x02013;30&#x02013;60&#x000a0;% discontinuous sucrose gradient at 45,000&#x000d7; <italic>g</italic> for 1&#x000a0;h at 4&#x000a0;&#x000b0;C. The VLP bands were collected and pelleted by high-speed centrifugation (45,000&#x000d7; <italic>g</italic> for 30&#x000a0;min). VLPs were resuspended in 500&#x000a0;&#x003bc;l phosphate-buffered saline (PBS) overnight at 4 &#x000b0;C and protein concentration was determined using a QuantiPro BCA Assay Kit (Sigma-Aldrich, St Louis, USA).</p></sec><sec id="Sec7"><title>Characterization of VLPs</title><p>VLPs were characterized by Western blots and electron microscopy. For Western blot analysis, mouse serum was used to probe T653K protein. Serum was from BALB/c mice infected with the <italic>T. spiralis</italic> Korean isolate. Serum was collected at week 4 after infection. Monoclonal mouse anti-M1 antibody was used to determine M1 protein content. For electron microscopy, negative staining of VLPs was performed followed by transmission electron microscopy (Tecnai G2 spirit), (FEI, Hillsboro, USA).</p></sec><sec id="Sec8"><title>VLP immunization schedule and challenge infection</title><p>Female, BALB/c mice (6&#x02013;8 week-old) were divided into 4 groups; na&#x000ef;ve control, <italic>T. spiralis</italic> infection control (TS control), T653K VLP and T653K VLP/CT. Mice were intramuscularly immunized with T653K VLPs with or without CT (25&#x000a0;&#x003bc;g VLPs/mouse, 2&#x000a0;&#x003bc;g CT/mouse, 10 mice in each group). All experimental groups were vaccinated at weeks 0 and 4. Four weeks after the last immunization, 10 mice of each group were challenged orally with 100&#x02009;<italic>T. spiralis</italic> (Korea isolate) larvae per mouse. Mice were sacrificed 6&#x000a0;weeks after challenge infection, larvae were collected from the mouse diaphragm and counted after the diaphragm was digested with artificial digestion solution (1&#x000a0;% HCl - 1.5&#x000a0;% pepsin). The rate of reduction in larval burden was calculated according to the recovered larvae per gram muscle. Blood was collected from the retro-orbital plexus on week 0, 1, 5, 8 before challenge and on week 1, 4 and 6 after challenge infection. Sera were separated and stored at -20&#x000a0;&#x000b0;C until analyzed for specific antibodies. All animal experiments and husbandry involved in these studies were conducted under the guidelines of the Kyung Hee University IACUC. Kyung Hee IACUC operates under the National Veterinary Research and Quarantine Service (NVRQS) and regulations of the World Organization for Animal Health (WOAH).</p></sec><sec id="Sec9"><title>Evaluation of humoral immune responses</title><p>Sera from experimental mice were used in an enzyme-linked immunosorbent assay (ELISA) to measure the levels of IgG, IgG1 and IgG2a against <italic>T. spiralis</italic> antigen. 96 well flat-immunoplate (SPL) were coated overnight at 4&#x000a0;&#x000b0;C with 100&#x000a0;&#x003bc;l of <italic>T. spiralis</italic> antigen at a concentration of 4&#x000a0;&#x003bc;g/ml in 0.05&#x000a0;M carbonate bicarbonate buffer (pH&#x000a0;9.6) per well. Serum samples diluted (1:100) in PBST (100&#x000a0;&#x003bc;l/well) were then added in duplicate.</p></sec><sec id="Sec10"><title>Cytokine analysis</title><p>Individual mouse spleens were collected 2.5&#x000a0;months after immunization from the immunized and na&#x000ef;ve groups. Single-cell suspensions were prepared from each spleen. Cells were incubated in 96-well flat culture plates for 2&#x000a0;days at 37&#x000a0;&#x000b0;C in the presence of 5&#x000a0;% CO<sub>2</sub>. Cells in 100&#x000a0;&#x003bc;l of RPMI-1640 were stimulated with 100&#x000a0;&#x003bc;l of 2&#x000a0;&#x003bc;g/ml&#x02009;<italic>T. spiralis</italic> ES Ag. For the cytokine assay, supernatants of spleen cell cultures were collected from each well by separation and stored at -20&#x000a0;&#x000b0;C until use. OptEIA sets (BD Bioscience, San Jose, CA, USA) were used to determine the concentration of interferon-gamma (IFN-&#x003b3;), interleukin (IL)-2, IL-4 and IL-10 in culture supernatants following the manufacturer&#x02019;s procedures.</p></sec><sec id="Sec11"><title>Statistics</title><p>All parameters were recorded for individuals within all groups. Statistical comparisons of data were carried out using the Kruskal-Wallis test and Paired t-test of PC-SAS 9.3. A <italic>P</italic>-value&#x02009;&#x0003c;&#x02009;0.05 was considered to be significant.</p></sec></sec><sec id="Sec12"><title>Results</title><sec id="Sec13"><title>Generation of constructs</title><p>The T653K gene from <italic>T. spiralis</italic> Korean isotype was amplified by PCR and the influenza M1 gene was amplified by RT-PCR with primers containing restriction enzyme sites (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>, <xref rid="Fig1" ref-type="fig">c</xref>). Genes were cloned into pFastBac vectors, and insertion of T653K and M1 in pFastBac expressing vectors was confirmed by cutting with restriction enzyme sites, T653K: BamHI and XbaI, M1: SmaI and XbaI (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>, <xref rid="Fig1" ref-type="fig">d</xref>). The nucleotide sequences of the T653K and M1 genes were found to be identical to the previously published sequences by DNA sequencing.<fig id="Fig1"><label>Fig. 1</label><caption><p>PCR identification of T653K and M1 genes and recombinant plasmids pFastBac-T653K and pFastBac-M1 digested. The <italic>T. spiralis</italic> T653K gene was PCR-amplified from cDNA synthesized using a Prime Script 1<sup>st</sup> Strain cDNA Synthesis Kit using total RNA extracted from <italic>T. spiralis</italic> Korean isotype (<bold>a</bold>). Influenza M1 gene was PCR amplified fromtotal RNA extracted from influenza virus (A/PR/8/34) (<bold>c</bold>). The <italic>T. spiralis</italic> T653K gene and influenza M1 gene were cloned into pFastBac with EcoRI/XhoI and SamI/XbaI enzymes, respectively, resulting in T653K plasmid (<bold>b</bold>) and M1 plasmid (<bold>d</bold>). Marker: DNA marker; size of T653K: 1,239&#x000a0;bp; size of M1: 1,027&#x000a0;bp</p></caption><graphic xlink:href="13071_2016_1662_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec14"><title>Production of VLPs</title><p>VLPs containing influenza T653K and M1 were produced as described in <xref rid="Sec2" ref-type="sec">Methods</xref>. VLPs were harvested from the culture supernatants of Sf9 cells co-infected with two individual rBVs that express either T653K or M1. The size and morphology of VLPs containing T653K and M1 were examined by electron microscopy. The morphology of VLPs resembles the shape of influenza virus with spikes on their surfaces (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref>). The particle sizes ranged from approximately 40 to 120&#x000a0;nm. These results show that VLPs expressing T653K and M1 were generated. The incorporation of T653K and M1 into VLPs was confirmed by western blot using antibodies described in the methods (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2b</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Characterization of virus-like particles (VLPs). Electron microscopy and VLP size determination. Negative staining of VLPs was performed followed by transmission electron microscopy (TEM). The size is between 40 and 120&#x000a0;nm (<bold>a</bold>). Western blot analysis. VLPs (20, 10, 5&#x000a0;&#x003bc;g) were loaded for SDS-PAGE. Polyclonal mouse anti-<italic>T. spiralis</italic> antibody was used to probe T653k protein and anti-M1 monoclonal antibody was used to determine M1 protein (<bold>b</bold>)</p></caption><graphic xlink:href="13071_2016_1662_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec15"><title>Humoral immune responses induced by immunization with T653k VLPs</title><p>Mouse sera collected at different time points after immunization were used to measure levels of specific anti-<italic>T. spiralis</italic> IgG and subtype (IgG1 and IgG2a) antibodies (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). Higher levels of <italic>T. spiralis-</italic>specific IgG were found in mice immunized with T653K VLPs with or without CT compared to na&#x000ef;ve controls on week 0, 1, 5 and 8, where T653K VLPs with CT showed better <italic>T. spiralis-</italic>specific IgG response than T653K VLP without CT, indicating CT was an effective adjuvant (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>; <italic>&#x003c7;</italic><sup>2</sup>&#x02009;= 7.2, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.0273). Higher levels of <italic>T. spiralis-</italic>specific IgG1 and IgG2a antibody responses were also detected in mice immunized with T653K VLPs with CT on week 0, 1, 5 and 8 after immunization compared to VLPs without CT. Higher level of <italic>T. spiralis</italic>-specific IgG2a was found than <italic>T. spiralis</italic>-specific IgG1, indicating that the IgG2a response was dominant (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>, <xref rid="Fig3" ref-type="fig">d</xref>; IgG1: <italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;6.4889, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.039; IgG2a: <italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;7.2, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.0273). Although the IgG2a antibody response was dominant, <italic>T. spiralis</italic>-specific IgG1 antibody was also observed (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>), indicating that T653K VLPs vaccination elicited Th1/Th2 mixed immune responses (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3c</xref>, <xref rid="Fig3" ref-type="fig">d</xref>).<fig id="Fig3"><label>Fig. 3</label><caption><p>Experimental schedule and <italic>T. spiralis-</italic>specific IgG subtype (IgG1 and IgG2a) responses upon immunization. Mice were immunized twice with VLPs as indicated with a 4-week interval. Challenge infection was performed at week 4 after last immunization (<bold>a</bold>). Enzyme-linked immunosorbent assay (ELISA) plates were coated with <italic>T. spiralis</italic> antigen, as indicated in <xref rid="Sec2" ref-type="sec">Methods</xref>. <italic>T. spiralis</italic>-specific IgG, IgG1 and IgG2a antibody responses in the sera were determined after prime and boost. Significant differences were found between group VLPs alone and group VLP with cholera toxin (CT) (<bold>b</bold>, <bold>c</bold> and <bold>d</bold>, *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05)</p></caption><graphic xlink:href="13071_2016_1662_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec16"><title><italic>Trichinella spiralis</italic>-specific antibody response after challenge infection</title><p>To determine antibody response profiles in serum upon challenge infections, groups of mice were orally challenge infected with <italic>T. spiralis</italic> Korean isolate at week 4 after boost. To better understand the protective immune responses induced by T653K VLPs vaccination after challenge infection, <italic>T. spiralis</italic>-specific IgG, IgG1 and IgG2a were determined in the sera at weeks 1, 4 and 6 after challenge infection (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>, <xref rid="Fig4" ref-type="fig">b</xref>, <xref rid="Fig4" ref-type="fig">c</xref>). IgG, IgG1 and IgG2a antibody isotypes were significantly increased in groups of mice that received vaccination compared to those in TS control mice (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 and <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, respectively), in which VLPs vaccination with CT showed higher IgG, IgG1 and IgG2a responses. Significant differences in IgG, IgG1 and IgG2a levels among groups at week 6 post-challenge were found (IgG: <italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;7.2, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.0273; IgG1: <italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;7.2, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.0273; IgG2a: <italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;6.4889, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.039). Significant differences between before and after challenges (week 6 post-challenge) were as follows: IgG: TS control: <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;39.99, <italic>P</italic>&#x02009;=&#x02009;0.0006; VLP: <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;16.95, P&#x02009;=&#x02009;0.0035; VLP&#x02009;+&#x02009;CT: <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;27.97, <italic>P</italic>&#x02009;=&#x02009;0.0013; IgG1: TS control: <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;25.7, <italic>P</italic>&#x02009;=&#x02009;0.0015; VLP: <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;21.49, <italic>P</italic>&#x02009;=&#x02009;0.0022; VLP&#x02009;+&#x02009;CT: <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;14.25, <italic>P</italic>&#x02009;=&#x02009;0.0049, and IgG2a: TS control: <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;1.08, <italic>P</italic>&#x02009;=&#x02009;0.3922; VLP: <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;5.48, <italic>P</italic>&#x02009;=&#x02009;0.0317; VLP&#x02009;+&#x02009;CT: <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;5.09, <italic>P</italic>&#x02009;=&#x02009;0.0364. Importantly, IgG, IgG1 and IgG2a antibody levels were also found to be significantly higher in sera post-challenge than those before challenge, indicating the establishment of infection of larvae in the muscle that induces higher immune response. Especially, IgG on week 4 and 6, IgG1 on week 1, 4 and 6, and IgG2a on week 6 were found to be significantly higher (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4a</xref>, <xref rid="Fig4" ref-type="fig">b</xref>, <xref rid="Fig4" ref-type="fig">c</xref>). The VLPs with CT adjuvant showed increased antibody responses compared to that without CT. Interestingly, upon challenge, mice immunized with T653k VLPs with CT showed IgG1-dominant responses (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4d</xref>). This suggests that vaccination with T653K VLPs with CT elicited an IgG1-dominant Th1/Th2-mixed immune responses.<fig id="Fig4"><label>Fig. 4</label><caption><p>
<italic>Trichinella spiralis-</italic>specific antibody responses upon challenge infection. Immunized mice were challenge-infected orally with <italic>T. spiralis</italic> Korean isotype at week 4 after boost and <italic>T. spiralis-</italic>specific IgG, IgG1 and IgG2a antibody responses (<bold>a</bold>, <bold>b</bold> and <bold>c</bold>, *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01) and the ratio of IgG1 to IgG2a in the sera were determined (<bold>d</bold>)</p></caption><graphic xlink:href="13071_2016_1662_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec17"><title>Protective immunity</title><p>To determine the efficacies of T653K VLP vaccine, groups of mice including na&#x000ef;ve control and vaccinated mice were challenged with 100 larvae of <italic>T. spiralis</italic> at week 8 after vaccination. Mice were sacrificed at week 6 post-challenge and larvae were collected from the diaphragm (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). As shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, the mice immunized with T653K VLPs with CT showed 53.2&#x000a0;% of larval reduction, and the mice immunized with T653K VLPs showed 34&#x000a0;% of worm reduction, respectively (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>, <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;4.46, <italic>P</italic>&#x02009;=&#x02009;0.021 and <italic>t</italic><sub>(44)</sub>&#x02009;=&#x02009;3.29, <italic>P</italic>&#x02009;=&#x02009;0.0462, respectively). The results demonstrated that the intramuscular immunization with T653K VLPs vaccine induced partial protection against challenge infection with <italic>T. spiralis</italic> Korean isolate larvae, and VLPs with adjuvant CT showed better protection.<fig id="Fig5"><label>Fig. 5</label><caption><p>Protection induced by vaccination. The larvae (per gram) from diaphragm were recovered from vaccinated mice after oral challenge infection with 100&#x02009;<italic>T. spiralis</italic> larvae. Asterisks indicate statistically significant differences (*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05; **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01) in worm recovery of the immunized groups compared to TS control group</p></caption><graphic xlink:href="13071_2016_1662_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec18"><title>Cytokine responses</title><p>The levels of IFN-&#x003b3;, IL-2, IL-4 and IL-10 from cytokine-secreting cells after immunization were determined as indicated in Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>. Significantly higher levels of IFN-&#x003b3; (<italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;8.9091, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.0116), IL-2 (<italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;9.8462, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.0073), IL-4 (<italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;8.0563, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.0178) and IL-10 (<italic>&#x003c7;</italic><sup>2</sup>&#x02009;=&#x02009;8.4049, <italic>df</italic>&#x02009;=&#x02009;2, <italic>P</italic>&#x02009;=&#x02009;0.0150) cytokines were produced in VLP&#x02009;+&#x02009;CT and VLP groups following <italic>T. spiralis</italic> antigen stimulation compared to na&#x000ef;ve controls, in which VLP&#x02009;+&#x02009;CT showed higher levels of cytokines compared to a VLP alone group. Since higher levels of Th1/Th2-like cytokines were found in VLP or VLP&#x02009;+&#x02009;CT groups, we concluded that Th1/Th2-mixed type of immune responses was induced (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05).<fig id="Fig6"><label>Fig. 6</label><caption><p>Cytokine responses. The levels of IFN-&#x003b3; (<bold>a</bold>), IL-2 (<bold>b</bold>), IL-4 (<bold>c</bold>) and IL-10 (<bold>d</bold>) from cytokine-secreting cells after immunization were determined. Significantly higher levels of IFN-&#x003b3;, IL-2, IL-4 and IL-10 cytokines were produced IN VLP&#x02009;+&#x02009;CT and VLP alone groups compared to na&#x000ef;ve controls (*<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01)</p></caption><graphic xlink:href="13071_2016_1662_Fig6_HTML" id="MO6"/></fig></p></sec></sec><sec id="Sec19"><title>Discussion</title><p>A VLP-induced protective immune response is different from DNA vaccine or protein vaccine. VLP vaccines are genetically engineered and produced in cell cultures. VLP vaccines contain multiple copies of protein antigens, inducing strong humoral and cellular immune responses [<xref ref-type="bibr" rid="CR12">12</xref>]. DNA vaccines present endogenously expressed antigens to the immune systems, showing relatively low immunogenicity [<xref ref-type="bibr" rid="CR23">23</xref>]. Recombinant protein vaccines consist of protein antigens produced in heterologous expression systems, inducing antibody response. Compared to VLP vaccines, DNA vaccine mainly induces cellular immunity. F DNA vaccine derived from respiratory syncytial virus (RSV) was not able to induce detectable levels of antibody responses [<xref ref-type="bibr" rid="CR23">23</xref>]. Compared to VLP vaccines, recombinant H5 HA vaccine is less immunogenic, and vaccination even with 5-fold higher dose did not induce protective immunity [<xref ref-type="bibr" rid="CR24">24</xref>]. Overall, VLPs offer many advantages in safety, immunogenicity and antigen stability. Taken together, VLP vaccines are promising vaccine candidates against different pathogens.</p><p>Virus-like particles (VLPs) represent one of the most exciting new vaccine technologies. VLPs do not contain any viral genetic material, and they have significant potential to elicit a strong immune response, without doing any actual harm [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. The early vaccines (live, inactivated, subunit) are no longer considered as the most appropriate for new vaccine development [<xref ref-type="bibr" rid="CR26">26</xref>]. Thus in our current study, for the first time, we used baculovirus expression/VLP technology in a parasite nematode to produce parasite VLPs containing <italic>T. spiralis</italic> T653K and influenza M1 proteins. Our findings provide evidence that T653K VLPs with cholera toxin (CT) or without CT can induce protective immunity against live <italic>T. spiralis</italic> larval infection. The adjuvanted VLPs vaccine significantly improved humoral responses and protection upon challenge infection compared to VLPs alone.</p><p><italic>Trichinella spiralis</italic> excretory-secretory (ES) protein has been demonstrated to induce protective immunity against <italic>T. spiralis</italic> infection. Immunization with <italic>T. spiralis</italic> ES protein elicited <italic>T. spiralis</italic>-specific IgG, IgG1 and IgG2a antibody responses [<xref ref-type="bibr" rid="CR16">16</xref>]. Vaccination with ES protein microencapsulated in methacrylic acid copolymers elevated the antigen-specific serum IgG1 and IgA antibody responses, inducing Th1/Th2 immune responses that are protective [<xref ref-type="bibr" rid="CR27">27</xref>]. Recombinant TspSP-1.2 protein derived from <italic>T. spiralis</italic> serine protease gene and Ts-ES-1 (20&#x000a0;kDa) secreted by <italic>T. spiralis</italic> induced partial protections, considering it is a potential candidate for vaccine development against <italic>T. spiralis</italic> infection [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. These recombinant proteins were produced from an <italic>E. coli</italic> expression system, and vaccine efficacy was not successful. In the current study, we used T653K derived from <italic>T. spiralis</italic> ES Ag 53&#x000a0;kDa as a surface protein of VLPs, for which vaccine efficacy has not been studied previously. Our study indicated that vaccination with <italic>T. spiralis</italic> T653K containing VLPs elicited <italic>T. spiralis</italic>-specific IgG, IgG1 and IgG2a antibody responses and partial protection against <italic>T. spiralis</italic> challenge in mice.</p><p>Results shown in the present study indicate that the pattern of IgG1 and IgG2a immune responses is affected by challenge infection. T653K VLPs vaccination induced higher level of <italic>T. spiralis</italic>-specific IgG2a antibodies before challenge and subsequent challenge infection significantly increased the levels of IgG1 antibodies (Figs.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, <xref rid="Fig4" ref-type="fig">4</xref>). An effective vaccine must direct T-helper cells toward the development of Th1, rather than Th2 responses. Moreover, a humoral response is necessary because specific antibodies limit the multiplication of parasite by killing extracellular parasite, either by activating the complement system or by opsonizing the parasites for phagocytosis and macrophage killing [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>]. Importantly, in the present study, IgG1 antibodies before challenge and IgG2a antibody after challenge infection were also induced, indicating a Th1/Th2-mixed type of immune response, which is important for protective immunity against <italic>T. spiralis</italic> infection [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Induction of IgG1 antibody responses upon challenge might be necessary since parasite-specific antibodies and the associated Th2 responses have been reported to limit worm establishment and may even play a role in diminishing the effect of challenge infections [<xref ref-type="bibr" rid="CR35">35</xref>]. Further studies are needed for better understanding of the immune mechanisms affecting the pattern of antibody isotypes induced by vaccination.</p><p>Cholera toxin (CT) is known to be a potent adjuvant. CT can induce maturation of dendritic cells and augment the priming of CD4<sup>+</sup> T cells and the antigen presentation by dendritic cells and B cells [<xref ref-type="bibr" rid="CR36">36</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. However, the role of CT adjuvant in parasite vaccine fields is unknown. In the present study, for the first time, we investigated protective efficacy in mice immunized with VLPs alone or with CT-adjuvanted VLPs. Cholera toxin (CT) has been widely shown to be effective as a potent mucosal vaccine adjuvant. There is a strong supporting report, in which cholera toxin by nonconventional adjuvant pathway induces protective memory responses after epicutaneous vaccination [<xref ref-type="bibr" rid="CR40">40</xref>]. In the present study, mice intramuscularly immunized with CT-adjuvanted VLPs showed significantly enhanced T653K VLP-induced <italic>T. spiralis</italic>-specific immune response. All immunized mice were partially protected against challenge infection with <italic>T. spiralis</italic>, in which mice immunized with CT-adjuvanted VLPs showed significant decrease in worm burden compared to mice immunized with VLPs alone (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>), indicating that the adjuvant plays an important role in enhancing the protective efficacy. Mice immunized with CT-adjuvanted VLPs showed significantly improved protection, indicating the use of a safe and effective adjuvant would have a significant impact for developing VLP vaccines. Since a careful selection of adjuvant is important depending on specific vaccine antigens and desired types of protective immunity, further studies are needed for better understanding of the immune mechanisms induced by adjuvants [<xref ref-type="bibr" rid="CR41">41</xref>].</p></sec><sec id="Sec20"><title>Conclusions</title><p>Overall, the present studies provide new insight into <italic>T. spiralis</italic> VLPs-induced protective efficacy. Intramuscular immunization with VLPs alone or with CT elicited a systemic Th1/Th2-mixed type of immune response and produced a partial protection against <italic>T. spiralis</italic> infection in mice. CT-adjuvanted VLPs showed significantly increased immunogenicity.</p></sec><sec id="Sec21"><title>Abbreviations</title><p>CT, cholera toxin; ELISA, enzyme-linked immunosorbent assay; ES, excretory/secretory; HRP, Horseradish peroxidase; PBS, phosphate-buffered saline; SD&#x02019;, Sprague&#x02013;Dawley; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; VLP, virus-like particle.</p></sec></body><back><app-group><app id="App1"><sec id="Sec22"><title>Additional file</title><p><media position="anchor" xlink:href="13071_2016_1662_MOESM1_ESM.pdf" id="MOESM1"><label>Additional file 1: Figure S1.</label><caption><p>
<italic>Trichinella spiralis</italic> ES product was separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) in 12 % polyacrylamide gels using a Mini-PROTEAN Tetra Cell electrophoresis unit (Bio-Rad, USA). <italic>Trichinella spiralis</italic> ES product (40, 20, 10, 5 &#x003bc;g) was loaded and incubated at 150 V for 1 h. To determine the proteins in <italic>T. spiralis</italic> ES product, the gel was stained with coomassie blue. <italic>Trichinella spiralis</italic> T653k protein was detected in <italic>T. spiralis</italic> ES product. (PDF 45 KB)</p></caption></media></p></sec></app></app-group><ack><title>Acknowledgements</title><p>We thank Dr. Compans W. Richard for providing great help in improving manuscript.</p><sec id="FPar1"><title>Funding</title><p>This work was supported by a grant from the National Research Foundation of Korea (NRF) (NRF-2014R1A2A2A01004899), a grant from the Agri-Bio Industry Technology Development Program (315030-03-1-HD020), IPET, MAFRA, KHIDI, and a grant from the Ministry of Health and Welfare, Republic of Korea (HI15C2928).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>Data supporting the conclusions of this article are included within the article.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>SH carried out the molecular genetic studies, participated in the sequence alignment, prepared VLPs and drafted the manuscript. SS carried out analysis and interpretation of data. DH and AR carried out animal experiment. FQ carried out the experiment design, analysis and interpretation of data and drafted the manuscript. All authors read and approved the final version of the manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval</title><p>All animal experiments and husbandry involved in these studies were conducted under the guidelines of the Kyung Hee University IACUC. Kyung Hee IACUC operates under the National Veterinary Research and Quarantine Service (NVRQS) and regulations of the World Organization for Animal Health (WOAH).</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murrell</surname><given-names>KD</given-names></name><name><surname>Pozio</surname><given-names>E</given-names></name></person-group><article-title>Worldwide occurrence and impact of human trichinellosis, 1986&#x02013;2009</article-title><source>Emerging Infect Dis</source><year>2011</year><volume>17</volume><issue>12</issue><fpage>2194</fpage><lpage>2202</lpage><pub-id pub-id-type="doi">10.3201/eid1712.110896</pub-id><pub-id pub-id-type="pmid">22172230</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurdova-Mintcheva</surname><given-names>R</given-names></name><name><surname>Jordanova</surname><given-names>D</given-names></name><name><surname>Ivanova</surname><given-names>M</given-names></name></person-group><article-title>Human trichinellosis in Bulgaria&#x000a0;-&#x000a0;epidemiological situation and trends</article-title><source>Vet Parasitol</source><year>2009</year><volume>159</volume><issue>3</issue><fpage>316</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2008.10.070</pub-id><pub-id pub-id-type="pmid">19084338</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribicich</surname><given-names>M</given-names></name><name><surname>Gamble</surname><given-names>H</given-names></name><name><surname>Bolpe</surname><given-names>J</given-names></name><name><surname>Scialfa</surname><given-names>E</given-names></name><name><surname>Krivokapich</surname><given-names>S</given-names></name><name><surname>Cardillo</surname><given-names>N</given-names></name><etal/></person-group><article-title><italic>Trichinella</italic> infection in wild animals from endemic regions of Argentina</article-title><source>Parasitol Res</source><year>2010</year><volume>107</volume><issue>2</issue><fpage>377</fpage><lpage>380</lpage><pub-id pub-id-type="doi">10.1007/s00436-010-1873-3</pub-id><pub-id pub-id-type="pmid">20424859</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>G</given-names></name><name><surname>Choi</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>YM</given-names></name><name><surname>Jeon</surname><given-names>HJ</given-names></name><name><surname>Jung</surname><given-names>Y</given-names></name><etal/></person-group><article-title>An outbreak of trichinellosis with detection of <italic>Trichinella</italic> larvae in leftover wild boar meat</article-title><source>J Korean Med Sci</source><year>2011</year><volume>26</volume><issue>12</issue><fpage>1630</fpage><lpage>1633</lpage><pub-id pub-id-type="doi">10.3346/jkms.2011.26.12.1630</pub-id><pub-id pub-id-type="pmid">22148002</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pompa-Mera</surname><given-names>E</given-names></name><name><surname>Y&#x000e9;pez-Mulia</surname><given-names>L</given-names></name><name><surname>Ocana-Mondragon</surname><given-names>A</given-names></name><name><surname>Garcia-Zepeda</surname><given-names>E</given-names></name><name><surname>Ortega-Pierres</surname><given-names>G</given-names></name><name><surname>Gonzalez-Bonilla</surname><given-names>C</given-names></name></person-group><article-title><italic>Trichinella spiralis</italic>: intranasal immunization with attenuated <italic>Salmonella enterica</italic> carrying a gp43 antigen-derived 30mer epitope elicits protection in BALB/c mice</article-title><source>Exp Parasitol</source><year>2011</year><volume>129</volume><issue>4</issue><fpage>393</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2011.08.013</pub-id><pub-id pub-id-type="pmid">21907709</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Vaccination of mice with DNA vaccine induces the immune response and partial protection against <italic>T. spiralis</italic> infection</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><issue>8</issue><fpage>1205</fpage><lpage>1212</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.08.104</pub-id><pub-id pub-id-type="pmid">16202484</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Zhan</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Heat shock protein 70 from <italic>Trichinella spiralis</italic> induces protective immunity in BALB/c mice by activating dendritic cells</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><issue>35</issue><fpage>4412</fpage><lpage>4419</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.06.055</pub-id><pub-id pub-id-type="pmid">24962751</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Oral administration with attenuated <italic>Salmonella</italic> encoding a <italic>Trichinella</italic> cystatin-like protein elicited host immunity</article-title><source>Exp Parasitol.</source><year>2014</year><volume>141</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2014.03.015</pub-id><pub-id pub-id-type="pmid">24636891</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group><article-title><italic>Trichinella spiralis</italic>: characterization of phage-displayed specific epitopes and their protective immunity in BALB/c mice</article-title><source>Exp Parasitol</source><year>2008</year><volume>118</volume><issue>1</issue><fpage>66</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2007.06.014</pub-id><pub-id pub-id-type="pmid">17707815</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGuire</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>WC</given-names></name><name><surname>Wakelin</surname><given-names>D</given-names></name></person-group><article-title>Nasal immunization with homogenate and peptide antigens induces protective immunity against <italic>Trichinella spiralis</italic></article-title><source>Infect Immun</source><year>2002</year><volume>70</volume><issue>12</issue><fpage>7149</fpage><lpage>7152</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.12.7149-7152.2002</pub-id><pub-id pub-id-type="pmid">12438399</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Liu P, Chi J, Liu RD, Wang M, Jiang P, Liu LN, Long SR, Li LG, Zhang SB, Zhang XZ, Wang ZQ. Protective immunity aginst <italic>Trichinella spiralis</italic> infection induced by TsNd vaccine in mice. Parasit Vectors. 2015;28(8):185&#x02013;195.</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akahata</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Andersen</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Holdaway</surname><given-names>HA</given-names></name><name><surname>Kong</surname><given-names>W</given-names></name><etal/></person-group><article-title>A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection</article-title><source>Nat Med</source><year>2010</year><volume>16</volume><issue>3</issue><fpage>334</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/nm.2105</pub-id><pub-id pub-id-type="pmid">20111039</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adolph</surname><given-names>KW</given-names></name><name><surname>Butler</surname><given-names>PJ</given-names></name></person-group><article-title>Assembly of a spherical plant virus</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>1976</year><volume>276</volume><issue>943</issue><fpage>113</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1098/rstb.1976.0102</pub-id><pub-id pub-id-type="pmid">13422</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Chuan</surname><given-names>YP</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Middelberg</surname><given-names>AP</given-names></name></person-group><article-title>Modeling the competition between aggregation and self&#x02010;assembly during virus&#x02010;like particle processing</article-title><source>Biotechnol Bioeng</source><year>2010</year><volume>107</volume><issue>3</issue><fpage>550</fpage><lpage>560</lpage><pub-id pub-id-type="doi">10.1002/bit.22821</pub-id><pub-id pub-id-type="pmid">20521301</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chromy</surname><given-names>LR</given-names></name><name><surname>Pipas</surname><given-names>JM</given-names></name><name><surname>Garcea</surname><given-names>RL</given-names></name></person-group><article-title>Chaperone-mediated in vitro assembly of Polyomavirus capsids</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><issue>18</issue><fpage>10477</fpage><lpage>10482</lpage><pub-id pub-id-type="doi">10.1073/pnas.1832245100</pub-id><pub-id pub-id-type="pmid">12928495</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>F</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Timothy</surname><given-names>O</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Immunization with <italic>Trichinella spiralis</italic> Korean isolate larval excretory-secretory antigen induces protection and lymphocyte subset changes in rats</article-title><source>Immunol Invest</source><year>2004</year><volume>33</volume><issue>1</issue><fpage>15</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1081/IMM-120027681</pub-id><pub-id pub-id-type="pmid">15015829</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>The protective effect of the recombinant 53-kDa protein of <italic>Trichinella spiralis</italic> on experimental colitis in mice</article-title><source>Dig Dis Sci</source><year>2011</year><volume>56</volume><issue>10</issue><fpage>2810</fpage><lpage>2817</lpage><pub-id pub-id-type="doi">10.1007/s10620-011-1689-8</pub-id><pub-id pub-id-type="pmid">21476030</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Hu</surname><given-names>DD</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name></person-group><article-title>Proteomic analysis of <italic>Trichinella spiralis</italic> muscle larval excretory-secretory proteins recognized by early infection sera</article-title><source>Biomed Res Int.</source><year>2013</year><volume>2013</volume><fpage>139745</fpage><pub-id pub-id-type="pmid">23844355</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagano</surname><given-names>I</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name></person-group><article-title>Species-specific antibody responses to the recombinant 53-kilodalton excretory and secretory proteins in mice infected with <italic>Trichinella</italic> spp</article-title><source>Clin Vaccine Immunol</source><year>2008</year><volume>15</volume><issue>3</issue><fpage>468</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1128/CVI.00467-07</pub-id><pub-id pub-id-type="pmid">18184826</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>P</given-names></name><name><surname>Bolas-Fernandez</surname><given-names>F</given-names></name><name><surname>Wakelin</surname><given-names>D</given-names></name></person-group><article-title>Immunization of mice against <italic>Trichinella spiralis</italic> and <italic>T. britovi</italic> using excretory and secretory antigens</article-title><source>J Helminthol</source><year>1997</year><volume>71</volume><issue>02</issue><fpage>109</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1017/S0022149X00015765</pub-id><pub-id pub-id-type="pmid">9192714</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>F</given-names></name><name><surname>Matsumoto</surname><given-names>T</given-names></name><name><surname>Shin</surname><given-names>Y</given-names></name><name><surname>Min</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Othman</surname><given-names>T</given-names></name><etal/></person-group><article-title>Relationships between IgG, IgM, IgE and resistance to reinfection during the early phase of infection with <italic>Clonorchis sinensis</italic> in rats</article-title><source>Immunol Invest</source><year>2004</year><volume>33</volume><issue>1</issue><fpage>51</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1081/IMM-120027684</pub-id><pub-id pub-id-type="pmid">15015832</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>K</given-names></name><name><surname>Bellaby</surname><given-names>T</given-names></name><name><surname>Wakelin</surname><given-names>D</given-names></name></person-group><article-title>Immunity to <italic>Trichinella spiralis</italic> transferred by serum from vaccinated mice not protected by immunization</article-title><source>Parasite Immunol</source><year>1995</year><volume>17</volume><issue>2</issue><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3024.1995.tb00970.x</pub-id><pub-id pub-id-type="pmid">7761112</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Kwon</surname><given-names>Y</given-names></name><name><surname>Hwang</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Ko</surname><given-names>E</given-names></name><name><surname>Yoo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Baculovirus-expressed virus-like particle vaccine in combination with DNA encoding the fusion protein confers protection against respiratory syncytial virus</article-title><source>Vaccine</source><year>2014</year><volume>32</volume><issue>44</issue><fpage>5866</fpage><lpage>5874</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2014.08.045</pub-id><pub-id pub-id-type="pmid">25173478</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Hossain</surname><given-names>J</given-names></name><name><surname>Yoo</surname><given-names>D</given-names></name><name><surname>Lipatov</surname><given-names>AS</given-names></name><name><surname>Davis</surname><given-names>CT</given-names></name><name><surname>Quan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles</article-title><source>Virology</source><year>2010</year><volume>405</volume><issue>1</issue><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2010.05.034</pub-id><pub-id pub-id-type="pmid">20580392</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Quan</surname><given-names>F</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name></person-group><article-title>Influenza vaccines based on virus-like particles</article-title><source>Virus Res</source><year>2009</year><volume>143</volume><issue>2</issue><fpage>140</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2009.04.005</pub-id><pub-id pub-id-type="pmid">19374929</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitoiset</surname><given-names>F</given-names></name><name><surname>Vazquez</surname><given-names>T</given-names></name><name><surname>Bellier</surname><given-names>B</given-names></name></person-group><article-title>Enveloped virus-like particle platforms: vaccines of the future?</article-title><source>Expert Rev Vaccines</source><year>2015</year><volume>14</volume><issue>7</issue><fpage>913</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.1046440</pub-id><pub-id pub-id-type="pmid">25968245</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dea-Ayuela</surname><given-names>MA</given-names></name><name><surname>Rama-I&#x000f1;iguez</surname><given-names>S</given-names></name><name><surname>Bolas-Fern&#x000e1;ndez</surname><given-names>F</given-names></name></person-group><article-title>Vaccination of mice against intestinal <italic>Trichinella spiralis</italic> infections by oral administration of antigens microencapsulated in methacrilic acid copolymers</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><issue>15</issue><fpage>2772</fpage><lpage>2780</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.01.006</pub-id><pub-id pub-id-type="pmid">16446017</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>ZQ</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>HJ</given-names></name><name><surname>Liu</surname><given-names>LN</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name></person-group><article-title>Cloning, expression and characterization of a <italic>Trichinella spiralis</italic> serine protease gene encoding a 35.5&#x000a0;kDa protein</article-title><source>Exp Parasitol</source><year>2013</year><volume>134</volume><issue>2</issue><fpage>148</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.exppara.2013.03.004</pub-id><pub-id pub-id-type="pmid">23501807</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gu</surname><given-names>Y</given-names></name><name><surname>Zhan</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name></person-group><article-title>Partially protective immunity induced by a 20&#x000a0;kDa protein secreted by <italic>Trichinella spiralis</italic> stichocytes</article-title><source>PloS one</source><year>2015</year><volume>10</volume><issue>8</issue><fpage>e0136189</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0136189</pub-id><pub-id pub-id-type="pmid">26288365</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>LL</given-names></name><name><surname>Sayles</surname><given-names>PC</given-names></name></person-group><article-title>Deficient humoral responses underlie susceptibility to <italic>Toxoplasma gondii</italic> in CD4-deficient mice</article-title><source>Infect Immun</source><year>2002</year><volume>70</volume><issue>1</issue><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1128/IAI.70.1.185-191.2002</pub-id><pub-id pub-id-type="pmid">11748181</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Remington</surname><given-names>JS</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name></person-group><article-title>Decreased resistance of B cell-deficient mice to infection with <italic>Toxoplasma gondii</italic> despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase</article-title><source>J Immunol</source><year>2000</year><volume>164</volume><issue>5</issue><fpage>2629</fpage><lpage>2634</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.164.5.2629</pub-id><pub-id pub-id-type="pmid">10679102</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vercammen</surname><given-names>M</given-names></name><name><surname>Scorza</surname><given-names>T</given-names></name><name><surname>Bouhdidi</surname><given-names>A</given-names></name><name><surname>Beeck</surname><given-names>K</given-names></name><name><surname>Carlier</surname><given-names>Y</given-names></name><name><surname>Dubremetz</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Opsonization of <italic>Toxoplasma gondii</italic> tachyzoites with nonspecific immunoglobulins promotes their phagocytosis by macrophages and inhibits their proliferation in nonphagocytic cells in tissue culture</article-title><source>Parasite Immunol</source><year>1999</year><volume>21</volume><issue>11</issue><fpage>555</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3024.1999.00256.x</pub-id><pub-id pub-id-type="pmid">10583856</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cui</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name></person-group><article-title>Oral vaccination with Ts87 DNA vaccine delivered by attenuated Salmonella typhimurium elicits a protective immune response against <italic>Trichinella spiralis</italic> larval challenge</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><issue>15</issue><fpage>2735</fpage><lpage>2742</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.026</pub-id><pub-id pub-id-type="pmid">20105428</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deville</surname><given-names>S</given-names></name><name><surname>de Pooter</surname><given-names>A</given-names></name><name><surname>Aucouturier</surname><given-names>J</given-names></name><name><surname>Lain&#x000e9;-Prade</surname><given-names>V</given-names></name><name><surname>Cote</surname><given-names>M</given-names></name><name><surname>Boireau</surname><given-names>P</given-names></name><etal/></person-group><article-title>Influence of adjuvant formulation on the induced protection of mice immunized with total soluble antigen of <italic>Trichinella spiralis</italic></article-title><source>Vet Parasitol</source><year>2005</year><volume>132</volume><issue>1</issue><fpage>75</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.vetpar.2005.05.029</pub-id><pub-id pub-id-type="pmid">15990233</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackwell</surname><given-names>NM</given-names></name><name><surname>Else</surname><given-names>KJ</given-names></name></person-group><article-title>B cells and antibodies are required for resistance to the parasitic gastrointestinal nematode <italic>Trichuris muris</italic></article-title><source>Infect Immun</source><year>2001</year><volume>69</volume><issue>6</issue><fpage>3860</fpage><lpage>3868</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.6.3860-3868.2001</pub-id><pub-id pub-id-type="pmid">11349052</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagliardi</surname><given-names>MC</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Marinaro</surname><given-names>M</given-names></name><name><surname>Langenkamp</surname><given-names>A</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>De Magistris</surname><given-names>MT</given-names></name></person-group><article-title>Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming</article-title><source>Eur J Immunol</source><year>2000</year><volume>30</volume><issue>8</issue><fpage>2394</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1002/1521-4141(2000)30:8&#x0003c;2394::AID-IMMU2394&#x0003e;3.0.CO;2-Y</pub-id><pub-id pub-id-type="pmid">10940931</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lycke</surname><given-names>N</given-names></name></person-group><article-title>The mechanism of cholera toxin adjuvanticity</article-title><source>Res Immunol</source><year>1997</year><volume>148</volume><issue>8</issue><fpage>504</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1016/S0923-2494(98)80144-2</pub-id><pub-id pub-id-type="pmid">9588829</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freytag</surname><given-names>L</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name></person-group><article-title>Mucosal adjuvants</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><issue>15</issue><fpage>1804</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.010</pub-id><pub-id pub-id-type="pmid">15734046</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guebre-Xabier</surname><given-names>M</given-names></name><name><surname>Hammond</surname><given-names>SA</given-names></name><name><surname>Epperson</surname><given-names>DE</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Ellingsworth</surname><given-names>L</given-names></name><name><surname>Glenn</surname><given-names>GM</given-names></name></person-group><article-title>Immunostimulant patch containing heat-labile enterotoxin from <italic>Escherichia coli</italic> enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells</article-title><source>J Virol</source><year>2003</year><volume>77</volume><issue>9</issue><fpage>5218</fpage><lpage>5225</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.9.5218-5225.2003</pub-id><pub-id pub-id-type="pmid">12692224</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olvera-Gomez</surname><given-names>I</given-names></name><name><surname>Hamilton</surname><given-names>SE</given-names></name><name><surname>Xiao</surname><given-names>Z</given-names></name><name><surname>Guimaraes</surname><given-names>CP</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name><name><surname>Hogquist</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination</article-title><source>Proc Natl Acad Sci USA</source><year>2012</year><volume>109</volume><issue>6</issue><fpage>2072</fpage><lpage>2077</lpage><pub-id pub-id-type="doi">10.1073/pnas.1105771109</pub-id><pub-id pub-id-type="pmid">22308317</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>F</given-names></name><name><surname>Ko</surname><given-names>E</given-names></name><name><surname>Kwon</surname><given-names>Y</given-names></name><name><surname>Joo</surname><given-names>KH</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name></person-group><article-title>Mucosal adjuvants for influenza virus-like particle vaccine</article-title><source>Viral Immunol</source><year>2013</year><volume>26</volume><issue>6</issue><fpage>385</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1089/vim.2013.0013</pub-id><pub-id pub-id-type="pmid">24236855</pub-id></element-citation></ref></ref-list></back></article>